ImmuPharma (LON:IMM) Trading Down 1.2% – What’s Next?

ImmuPharma plc (LON:IMM) shares were down 1.2% during mid-day trading on Wednesday . The stock traded as low as GBX 2.66 ($0.04) and last traded at GBX 2.82 ($0.04). Approximately 1,212,708 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 8,673,481 shares. The stock had previously closed at GBX 2.86 ($0.04).

ImmuPharma Trading Down 1.2%

The firm has a 50 day moving average price of GBX 2.90 and a 200-day moving average price of GBX 2.73. The firm has a market cap of £11.99 million, a PE ratio of -4.88 and a beta of 1.53.

ImmuPharma (LON:IMM) last announced its quarterly earnings data on Monday, May 19th. The company reported GBX (0.60) (($0.01)) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Equities analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.